FOLH1 and neoplasm: With the co-injection of blocking agent, tumor uptake dropped to 4.78 ± 0.96% IA/cc, 7.46 ± 1.07% IA/cc p.i. and 8.62 ± 0.74% IA/cc at 1 h, 4 h, and 24 h, respectively, confirming the specificity of 64Cu-DOTHA2-PSMA at the tumor (with linear model of uptake vs. co-injection: p < 0.001 (Table S9), 4 h: p = 0.004 and 24 h: p = 0.004).